2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012. 142:1592-1609.
5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012. 55:2005-2023.
6. Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol 2016. 78:181-205.
7. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005. 42:132-138.
9. Betteridge DJ. What is oxidative stress? Metabolism 2000. 49(2 Suppl 1):3-8.
11. Yoshikawa T, Naito Y. What is oxidative stress? Jpn Med Assoc J 2002. 45:271-276.
16. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, Cook JL. Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 1999. 274:26071-26078.
17. Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res 2018. 1865:721-733.
25. Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. Am J Med 1986. 81:565-578.
26. Casini A, Sun RW, Ott I. Medicinal Chemistry of Gold Anticancer Metallodrugs. Berlin: Walter de Gruyter; 2018.
31. Kim NH, Oh MK, Park HJ, Kim IS. Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation. J Pharmacol Sci 2010. 113:246-254.
32. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009. 36:131-140.
33. Banning A, Brigelius-Flohé R. NF-kappaB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression. Antioxid Redox Signal 2005. 7:889-899.
36. Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006. 2006:re13.
37. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 2009. 13:533-544.